Merrimack Pharmaceuticals, Inc. (MACK) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Merrimack Pharmaceuticals, Inc.

MACK

NASDAQ

Unprofitable

224M

Biotechnology

15.14USD

0.01 ( 0.10%)

Market Closed (as of May 17, 19:59 EDT)

Relative Strenght

100

Volume Buzz

405%

Earning Acce

Dist 52w H.

Overview Chart

Quote Panel

Updated April 27, 2025

1W % 1M % 3M % 1Y 51667.20 %

Key Metrics

Market Cap
223.97M
Shares Outstanding
14.79M
Share in Float
9.66M
Dividende
15.1

Earning Date
No Data
Price Target
15.145
Average Volume
182633
Beta
1.416

Range
11.53-15.89
Industry
Biotechnology
Website
https://www.merrimack.com
Sector
Healthcare

Quote Panel

Updated April 27, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

0.99x

P/B Ratio

0.0

Debt/Equity

0.0%

Net Margin

$-0.1

EPS

How MACK compares to sector?

P/E Ratio

Fundamentals

Relative Strength

MACK

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

MACK

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

No Data Available

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q2.22

N/A

-0.04
vs -0.06

Q3.22

N/A

-0.03
vs -0.04

Q4.22

N/A

-0.03
vs -0.03

Q1.23

N/A

-0.02
vs -0.04

Q2.23

N/A

-0.03
vs -0.04

Q3.23

N/A

-0.02
vs -0.03

Q4.23

N/A

-0.01
vs -0.03

Q1.24

N/A

-0.03
vs -0.02

Q2.24

+4575%

1.34
vs -0.03

Q3.24

+7807%

1.54
vs -0.02

Sales Growth

YoY

Current

Estimates

Q4.21

NA vs NA

Q1.22

NA vs NA

Q2.22

NA vs NA

Q3.22

NA vs NA

Q4.22

-445000.00 vs NA

Q1.23

NA vs NA

Q2.23

NA vs NA

Q3.23

NA vs NA

Q4.23

+100%

NA vs -445000

Q1.24

NA vs NA

Return on Equity

QoQ

Q2.22

-3%

-0.03
vs -0.01

Q3.22

-2%

-0.02
vs -0.03

Q4.22

-3%

-0.03
vs -0.02

Q1.23

-0.00
vs -0.03

Q2.23

-2%

-0.02
vs -0.00

Q3.23

-1%

-0.01
vs -0.02

Q4.23

-1%

-0.01
vs -0.01

Q1.24

-11%

-0.11
vs -0.01

Institutionnal Ownership

QoQ

Q4.22

53
vs 42

26%

Q1.23

55
vs 53

Q2.23

66
vs 55

20%

Q3.23

69
vs 66

Q4.23

73
vs 69

Q1.24

71
vs 73

-3%

Q2.24

6
vs 71

-92%

Q4.24

1
vs NA

Earnings Growth

Latest News

businesswire.com

16 hours ago

Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock

businesswire.com

16 hours ago

Merrimack Receives $225 Million Milestone Payment from Ipsen

businesswire.com

16 hours ago

Merrimack Reports Full Year 2023 Financial Results

businesswire.com

16 hours ago

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

businesswire.com

16 hours ago

Merrimack Reports Third Quarter 2023 Financial Results

businesswire.com

17 hours ago

Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution

Company Description

15.14USD

N/A

0.00x

0.99x

0.0

0.0%

$-0.1

Earnings Growth

Latest News

Company Description

15.14USD

N/A

0.00x

0.99x

0.0

0.0%

$-0.1